A small-molecule inhibitor of the enzyme NNMT studied preclinically for adipocyte metabolism and the NAD+/methylation axis. Evidence is limited to cell and rodent work; there are no human trials and it is not approved for human use.
5-Amino-1MQ (5-amino-1-methylquinolinium) blocks an enzyme called NNMT (nicotinamide N-methyltransferase) that is highly active in fat tissue. In laboratory and rodent studies, inhibiting NNMT increased the energy fat cells burn and reduced fat accumulation.
The rationale ties into the NAD+ and methylation systems: NNMT consumes nicotinamide (a building block the cell uses to regenerate NAD+) and a methyl donor called SAM. Blocking it is thought to spare those pools and nudge fat-cell metabolism toward higher energy expenditure.
Importantly, the evidence is preclinical — cell cultures and diet-induced-obesity mouse models. There are no published human trials, no established human dosing or safety data, and it is supplied strictly for laboratory research, not human use.
Searching the published record…
Searching the published record…
Searching the published record…
No indexed animal studies found for this term. Try the live PubMed query below.
Search this category on PubMed →No indexed in vitro studies found for this term. Try the live PubMed query below.
Search this category on PubMed →Studies are surfaced live from the U.S. National Library of Medicine (PubMed). biohackr indexes and links the published record; it does not host or alter source articles.